Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

TSX:MSCL

Satellos Bioscience Inc.

Last Close

0.48

26/07 19:45

Market Cap

56.40M

Beta: -

Volume Today

17.26K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics